14/04/2026
🧬 Last week, Institute for Regeneration and Repair spinout, Trogenix, took a major step towards eradicating one of the most aggressive forms of brain cancer.
The findings, published in Nature Magazine, highlight complete tumour eradication in 83% of cases in a pre-clinical model of glioblastoma. Through a new gene therapy approach, the treatment not only destroyed tumours but also activated the immune system to prevent them from returning, all without damaging healthy brain tissue. 🧠
With Trogenix now a step closer to clinical trials, this offers patients and families facing the devastating disease a real hope for more effective treatments.
Speaking on next steps, Chief Scientific Officer of Trogenix, Professor Steve Pollard, said: "We are committed to moving these findings as quickly and safely as possible to patients and are optimistic that this can provide a new approach to tackling solid tumours."
The end goal of all the work done at Edinburgh BioQuarter is to have a real-world impact and help those facing some of the toughest health challenges. This research is a stellar example of the innovation and breakthroughs our community of life-science experts can achieve when they collaborate and bring their vast experience and knowledge together.
Discover more about the ground-breaking research here: https://go.nature.com/4tGG1HS